Details of the Drug Combination

General Information of Drug Combination (ID: DCFCHTQ)

• Drug Combination Name: CUDC-101 + BIIB-021
• Indication: Diffuse intrinsic pontine glioma; Status: Investigative [1]
• Component Drugs:
  CUDC-101 (DM9ZOMD): Small molecular drug
  BIIB-021 (DMPAJ41): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: SU-DIPG-XIII
  Zero Interaction Potency (ZIP) Score: 2.52
  Bliss Independence Score: 4.153
  Loewe Additivity Score: 0.814
  LHighest Single Agent (HSA) Score: 3.921

Molecular Interaction Atlas of This Drug Combination

Indication(s) of CUDC-101

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

CUDC-101 Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Erbb2 tyrosine kinase receptor (HER2)	TT6EO5L	ERBB2_HUMAN	Modulator	[2]
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Modulator	[2]

Indication(s) of BIIB-021

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Phase 2	[3]

BIIB-021 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Heat shock protein 90 alpha (HSP90A)	TT78R5H	HS90A_HUMAN	Inhibitor	[4]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 1;21(7):1566-73.
• [3] ClinicalTrials.gov (NCT00618319) An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST). U.S. National Institutes of Health.
• [4] BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther. 2009 Apr;8(4):921-9.